Stockscreener 앱 받기
8.81
4.88%
0.41
시장 영업 전:
8.79
-0.02
-0.23%
전일 마감가:
$8.40
열려 있는:
$8.49
하루 거래량:
3.57M
Relative Volume:
0.70
시가총액:
$1.41B
수익:
$793.74M
순이익/손실:
$-398.71M
주가수익비율:
-2.7531
EPS:
-3.2
순현금흐름:
$-514.43M
1주 성능:
+3.59%
1개월 성능:
+1.26%
6개월 성능:
-36.39%
1년 성능:
+117.53%
1일 변동 폭
$8.465
$8.92
1주일 범위
$8.35
$9.14
52주 변동 폭
$3.5324
$23.86
노바백스 Stock (NVAX) Company Profile
명칭
Novavax Inc
전화
240-268-2000
주소
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
NVAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.81 | 1.41B | 793.74M | -398.71M | -514.43M | -3.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
노바백스 Stock (NVAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-05-10 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-08-09 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | 재확인 | B. Riley Securities | Buy |
| 2022-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-02 | 개시 | Jefferies | Hold |
| 2022-09-22 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-20 | 개시 | BofA Securities | Underperform |
| 2022-02-23 | 재확인 | B. Riley Securities | Buy |
| 2022-02-22 | 재개 | Jefferies | Buy |
| 2022-01-21 | 개시 | Cowen | Outperform |
| 2021-05-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-05 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | 재확인 | B. Riley FBR | Buy |
| 2020-06-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-05-28 | 재확인 | B. Riley FBR | Buy |
| 2020-05-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-27 | 재개 | B. Riley FBR | Buy |
| 2019-08-14 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-28 | 다운그레이드 | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-11 | 개시 | Oppenheimer | Outperform |
| 2018-11-26 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2018-03-29 | 업그레이드 | Seaport Global Securities | Neutral → Buy |
모두보기
노바백스 주식(NVAX)의 최신 뉴스
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax, Inc. (NASDAQ:NVAX) Receives $17.83 Average PT from Analysts - MarketBeat
Novavax, Inc. (NVAX) Stock: The Under-the-Radar Stock Poised for Massive Upside in 2025 - Insider Monkey
10 Under-the-Radar Stocks with Massive Upside for 2025 - Insider Monkey
Novavax climbs as FDA lifts clinical hold on Covid, flu combo trials - MSN
Analysts Set Novavax, Inc. (NASDAQ:NVAX) PT at $17.83 - MarketBeat
Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz - MSN
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Bird Flu Raising Red Flags Among Health Officials, CDC Urges Faster Testing - Benzinga
Moderna Dropped by 20% This Week -- Is It a Smart Buy Right Now? - The Motley Fool
Novavax Cashes In On Its COVID Albatross -- Challenges Remain (Rating Upgrade) - Seeking Alpha
Novavax (NVAX) Rises But Trails Market: What Investors Should Know - Yahoo Finance
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
Novavax Slips 7.3% After 2024 Revenue Guidance Reaffirmed - MarketWatch
Looking Into Novavax's Recent Short Interest - Benzinga
Why Novavax (NVAX) Stock Is Falling - Benzinga
Novavax: presents its 2025 growth strategy - Marketscreener.com
Novavax Shares Strategic Updates at Healthcare Conference - TipRanks
We Asked Retail If Novavax Stock Is A Buy At Current Levels: Nearly 70% Think It's Undervalued - MSN
Novavax to complete data submission to FDA by end of the year for authorization of its coronavirus vaccine - WPSD Local 6
(NVAX) On The My Stocks Page - Stock Traders Daily
Why Novavax Stock Is Volatile This Week - Benzinga
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Novavax (NASDAQ:NVAX) Stock Price Down 8.2%Time to Sell? - MarketBeat
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies - Benzinga
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax (NASDAQ:NVAX) surges 35% this week, taking five-year gains to 171% - Yahoo Finance
Strength Seen in Novavax (NVAX): Can Its 10.9% Jump Turn into More Strength? - MSN
Vaccine Stocks Jump After CDC Reports First US Bird-Flu Death - Yahoo Finance
Health Care Up as Vaccine Makers Surge -- Health Care Roundup - Marketscreener.com
Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike - Yahoo! Voices
Options Alert: Why Novavax (NVAX) Could Be The Biotech Hero Of Trump 2.0 - Barchart
Novavax (NASDAQ:NVAX) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Novavax Target of Unusually High Options Trading (NASDAQ:NVAX) - MarketBeat
Moderna, Novavax Stocks Climb Pre-Market On Growing Bird Flu Concerns: Retail Engagement Soars - MSN
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally - Benzinga
Novavax (NVAX) Shares Cross Above 200 DMA - Nasdaq
Moderna, Novavax and other vaccine names extend gains amid COVID/flu concerns - Seeking Alpha
Why Novavax (NVAX) Stock Is Rising - Benzinga
Insiders At Novavax Sold US$713k Of Stock Potentially Indicating Weakness - Simply Wall St
Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls - AOL
Insider Sell: James Young Sells 10,000 Shares of Novavax Inc (NV - GuruFocus.com
Novavax, Inc. (NASDAQ:NVAX) Director James F. Young Sells 4,600 Shares - MarketBeat
Novavax, Inc. (NASDAQ:NVAX) Director James F. Young Sells 5,400 Shares - MarketBeat
Novavax, Inc. (NASDAQ:NVAX) Director Rachel K. King Sells 4,150 Shares - MarketBeat
Novavax director Rachel King sells $37,435 in stock - Investing.com
Novavax director James Young sells shares worth $82,208 - Investing.com
Novavax director Rachel King sells $37,435 in stock By Investing.com - Investing.com UK
Novavax (NASDAQ:NVAX) Trading Up 6.6%Still a Buy? - MarketBeat
NVAX February 14th Options Begin Trading - Nasdaq
Novavax completes $200 million facility sale to Novo Nordisk By Investing.com - Investing.com Australia
노바백스 (NVAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):